ホーム › 食道癌 › ニューヨーク › New York City
New York City、NYにおける食道癌の臨床試験
New York Cityとその周辺地域（約30マイル以内）の拠点で、食道癌に関する22件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
被験者募集中第1相
- NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York
- NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York
- Icahn School of Medicine at Mount Sinai, New York
- 他2件
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
被験者募集中観察研究健康なボランティア歓迎
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
被験者募集中第2相
- Memorial Sloan Kettering Hospital, New York
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
被験者募集中第2相
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
被験者募集中第1相
- New York University (NYU) Langone Medical Center, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
被験者募集中第1相
- New York University (NYU) Clinical Cancer Center, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
被験者募集中第1/2相
- Columbia University, New York
- NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
被験者募集中第1相
- Memorial Sloan Kettering Cancer Center Head Neck Services, New York
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
被験者募集中第3相
- Icahn School of Medicine at Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of 2141-V11 in People With Esophageal, Gastric, or Gastroesophageal Junction Adenocarcinoma
被験者募集中第1/2相
- Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
被験者募集中第1相
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
被験者募集中第3相
- Research Site, New York
- Research Site, New York
- Research Site, New York
Retrospective Review of Esophageal Cancer at MSKCC
被験者募集中観察研究
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
被験者募集中第1相
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
被験者募集中観察研究健康なボランティア歓迎
- Columbia University Medical Center, New York
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
被験者募集中第1/2相
- Mt. Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
被験者募集中第2相
- Memorial Sloan Kettering Cancer Center, New York
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
被験者募集中第1相
- North Shore Hematology Oncology Associates P.C. DBA New York Cancer and Blood Specialists, New York
- Columbia University Irving Medical Center, New York
Registry for Esophageal and Gastroesophageal Junction Cancer
被験者募集中観察研究
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Brodalumab in the Treatment of Immune-Related Adverse Events
被験者募集中第1相
- Columbia University Irving Medical Center, New York
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
被験者募集中第1/2相
- Weill Cornell Medicine, Cornell University (site 126), New York
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, New York
他の都市における食道癌の試験
- Houston, TX36件の研究
- Boston, MA23件の研究
- Nashville, TN19件の研究
- St. Louis, MO17件の研究
- Pittsburgh, PA15件の研究
- Los Angeles, CA15件の研究
- Baldwin Park, CA14件の研究
- Grand Rapids, MI14件の研究
- Philadelphia, PA13件の研究
- San Antonio, TX12件の研究
- Dallas, TX11件の研究
- Arlington, VA11件の研究
New York Cityにおける他の研究
- 乳がん136件の研究
- 非小細胞肺癌121件の研究
- がん（全種類）109件の研究
- 前立腺がん103件の研究
- 転移性癌93件の研究
- 大腸癌78件の研究
- 卵巣がん69件の研究
- 肺がん60件の研究
- 多発性骨髄腫60件の研究
- 膵臓がん60件の研究
- 子宮内膜がん52件の研究
- 急性骨髄性白血病51件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。